Treatment Continuity Act of 2025

Section 509 of the Public Health Service Act (42 U.S.C. 290bb–2) is amended—

(1) in the section heading, by inserting AND SERIOUS MENTAL ILLNESS after SUBSTANCE USE DISORDER;

(2) in subsection (a)—

(A) in the matter preceding paragraph (1), by inserting and serious mental illness after substance use disorder; and

(B) by striking paragraphs (1) through (3) and inserting the following:

(1) access to long-acting injectable medications that are approved by the Food and Drug Administration for the treatment of individuals with substance use disorders or serious mental illness;

(2) lab testing and supportive counseling for substance use disorder and serious mental illness; and

(3) training on the use of long-acting injectable medications for the purposes described in paragraph (1), in combination with associated clinical services such as counseling.

(3) in subsection (b)—

(A) in the subsection heading, by inserting and Serious Mental Illness after Substance Use Disorder; and

(B) in paragraphs (1) and (2), by inserting and serious mental illness after substance use disorder;

(4) by striking subsections (d) and (e) and inserting the following:; and

Not later than 1 year after the date of enactment of the Treatment Continuity Act of 2025, and annually thereafter during the term of the program under this section, the Secretary shall transmit to Congress a report on the outcomes of such program, including completed or substantial progress toward treatment requirements based on clinician assessment.

(5) by redesignating subsection (f) as subsection (e).

The amendments made by this section shall apply to grants made under section 509 of the Public Health Service Act after the date of the enactment of this Act.